Sebastian Mayer1, Severine Iborra2, Donata Grimm3, Lisa Steinsiek3, Sven Mahner4, Michaela Bossart1, Linn Woelber3, Pit Jacob Voss5, Gerald Gitsch1, Annette Hasenburg6. 1. Department of Obstetrics and Gynecology, University Medical Center Freiburg, Freiburg, Germany. 2. Department of Obstetrics and Gynecology, University Medical Center Aachen, Aachen, Germany. 3. Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 4. Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany. 5. Department of Oral and Maxillofacial Surgery, University Medical Center Freiburg, Freiburg, Germany. 6. Department of Gynecology and Obstetrics, University Medical Center Mainz, Mainz, Germany. annette.Hasenburg@unimedizin-mainz.de.
Abstract
OBJECTIVE: Sexual activity (SA) and functioning (SF) are important factors influencing quality of life (QoL). Anticancer treatment can cause or promote sexual dysfunctions. In this study we analyzed the SA, SF and QoL in patients after completion of treatment for breast cancer (BC) and ovarian cancer (OC). METHODS: In this retrospective multicenter study 396 BC patients and 93 OC patients aged between 18 and 70 years were surveyed at least 24 months after cancer diagnosis and compared to 60 healthy women. Data were collected through validated questionnaires (Sexual Activity Questionnaire, Female Sexual Function Index-d, EORTC Quality of Life Questionnaire-C30). RESULTS: 45.9% of BC patients and 56.5% of OC patients reported SA. SF and well-being of sexually active BC patients were not influenced by the type and radicality of surgery or the administration of chemotherapy. Patients who received antihormonal therapy at the time of evaluation showed a lower frequency of SA (p = 0.007), less satisfaction (p = 0.003) and more discomfort during SA (p = < 0.001) compared to healthy controls but no differences in experiencing orgasms, health status, QoL and global health status. In contrast, BC patients without antihormonal therapy showed only a higher discomfort score (p = 0.028) than healthy controls and estimated their health status and QoL significantly better than patients who received antihormonal therapy (p = 0006). In general, SA was associated with a better health status (p = 0.007), a better QoL (p = 0.004) and a better global health status (p = 0.004) in BC patients. Sexually active OC patients showed no significant differences in SF, QoL and health status compared to healthy controls. CONCLUSIONS: Compared to healthy controls BC patients showed limitations in SF with a lower SA rate and more discomfort. Antihormonal therapy was an important factor influencing SF and well-being. Breast and OC survivors reported good physical and psychical health without differences in QoL and health status compared to controls. This might be explained by a change of perspective on life difficulties and altered priorities through a life threatening disease.
OBJECTIVE: Sexual activity (SA) and functioning (SF) are important factors influencing quality of life (QoL). Anticancer treatment can cause or promote sexual dysfunctions. In this study we analyzed the SA, SF and QoL in patients after completion of treatment for breast cancer (BC) and ovarian cancer (OC). METHODS: In this retrospective multicenter study 396 BC patients and 93 OC patients aged between 18 and 70 years were surveyed at least 24 months after cancer diagnosis and compared to 60 healthy women. Data were collected through validated questionnaires (Sexual Activity Questionnaire, Female Sexual Function Index-d, EORTC Quality of Life Questionnaire-C30). RESULTS: 45.9% of BC patients and 56.5% of OC patients reported SA. SF and well-being of sexually active BC patients were not influenced by the type and radicality of surgery or the administration of chemotherapy. Patients who received antihormonal therapy at the time of evaluation showed a lower frequency of SA (p = 0.007), less satisfaction (p = 0.003) and more discomfort during SA (p = < 0.001) compared to healthy controls but no differences in experiencing orgasms, health status, QoL and global health status. In contrast, BC patients without antihormonal therapy showed only a higher discomfort score (p = 0.028) than healthy controls and estimated their health status and QoL significantly better than patients who received antihormonal therapy (p = 0006). In general, SA was associated with a better health status (p = 0.007), a better QoL (p = 0.004) and a better global health status (p = 0.004) in BC patients. Sexually active OC patients showed no significant differences in SF, QoL and health status compared to healthy controls. CONCLUSIONS: Compared to healthy controls BC patients showed limitations in SF with a lower SA rate and more discomfort. Antihormonal therapy was an important factor influencing SF and well-being. Breast and OC survivors reported good physical and psychical health without differences in QoL and health status compared to controls. This might be explained by a change of perspective on life difficulties and altered priorities through a life threatening disease.
Entities:
Keywords:
Breast cancer; Ovarian cancer; Quality of life; Sexual activity; Sexual function
Authors: Luciana Silveira Campos; Simone Pellin De Nardi; Leo Francisco Limberger; Jose Manoel Caldas Journal: Support Care Cancer Date: 2022-02-28 Impact factor: 3.603
Authors: Debra L Barton; Stephanie L Pugh; Patricia A Ganz; Steven C Plaxe; Bridget F Koontz; Jeanne Carter; Natalya Greyz-Yusupov; Seth J Page; Kendrith M Rowland; Ernie P Balcueva; Sobia Nabeel; Jack B Basil; Matthew L Hill; Carolyn Y Muller; Maria C Bell; Snehal Deshmukh; Lisa A Kachnic Journal: J Clin Oncol Date: 2021-12-09 Impact factor: 44.544
Authors: Solveig K Smedsland; Kathrine F Vandraas; Synne K Bøhn; Alv A Dahl; Cecilie E Kiserud; Mette Brekke; Ragnhild S Falk; Kristin V Reinertsen Journal: Breast Cancer Res Treat Date: 2022-02-28 Impact factor: 4.872
Authors: Thais Sousa Rodrigues Guedes; Marcello Barbosa Otoni Gonçalves Guedes; Rebeca de Castro Santana; José Felipe Costa da Silva; Amanda Almeida Gomes Dantas; Mirari Ochandorena-Acha; Marc Terradas-Monllor; Javier Jerez-Roig; Dyego Leandro Bezerra de Souza Journal: Int J Environ Res Public Health Date: 2022-09-21 Impact factor: 4.614